CoChat

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Open access
Ng, Harry Ho Man, Lee, Ren Yuan, Goh, Siting, Tay, Isabel Shu Ying, Lim, Xinru, Lee, Bernett, Chew, Valerie, Li, Huihua, Tan, Benedict, Lim, Sherlly, Lim, Jeffrey Chun Tatt, Au, Bijin, Loh, Josh Jie Hua, Saraf, Sahil, Connolly, John Edward, Loh, Tracy, Leow, Wei Qiang, Lee, Joycelyn Jie Xin, Toh, Han Chong, Malavasi, Fabio, Lee, Ser Yee, Chow, Pierce, Newell, Evan W, Choo, Su Pin, Tai, David, Yeong, Joe, Lim, Tony Kiat Hon · 2020 · Journal for ImmunoTherapy of Cancer
Cited by 116

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we examined the expression of CD38, a molecule involved in the immunosuppressive adenosinergic pathway, on immune cells present in the tumor microenvironment. We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC. Methods: Clinically annotated samples from 49 patients with advanced HCC treated with ICB were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF) and multiplex cytokine analysis. Results: IHC and mIHC/IF analyses revealed that higher intratumoral CD38+ cell proportion was strongly associated with improved response to ICB. The overall response rates to ICB was significantly higher among patients with high proportion of total CD38+cells compared with patients with low proportion (43.5% vs 3.9%, p=0.019). Higher responses seen among patients with a high intratumoral CD38+cell proportion translated to a longer median progression-free survival (mPFS, 8.21 months vs 1.64 months, p=0.0065) and median overall survival (mOS, 19.06 months vs 9.59 months, p=0.0295). Patients with high CD38+CD68+macrophage density had a better mOS of 34.43 months compared with 9.66 months in patients with low CD38+CD68+ macrophage density. CD38 hi macrophages produce more interferon γ (IFN-γ) and related cytokines, which may explain its predictive value when treated with ICB. Conclusions: A high proportion of CD38+ cells, determined by IHC, predicts response to ICB and is associated with superior mPFS and OS in advanced HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000987

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 116

Metadata

Authors
Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B., Chew, V., Li, H., Tan, B., Lim, S., Lim, J. C. T., Au, B., Loh, J. J. H., Saraf, S., Connolly, J. E., Loh, T., Leow, W. Q., Lee, J. J. X., Toh, H. C., Malavasi, F., Lee, S. Y., Chow, P., Newell, E. W., Choo, S. P., Tai, D., Yeong, J., & Lim, T. K. H.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-08
Volume
8
Issue
2
Pages
e000987
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3080269113
Cited by
116
References
25
FWCI
5.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1136/jitc-2020-000987
The paper
Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B., Chew, V., Li, H., Tan, B., Lim, S., Lim, J. C. T., Au, B., Loh, J. J. H., Saraf, S., Connolly, J. E., Loh, T., Leow, W. Q., Lee, J. J. X., Toh, H. C., . . . Lim, T. K. H. (2020). Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.